OncoPlus – pro
The University of Chicago Molecular Pathology Laboratory Produce the OncoPlus universal cancer mutation analysis panel, a Next Generation Sequencing assay designed to interrogate over 1,200 solid tumor and hematological malignancy related genes via analysis of Peripheral Blood, Bone Marrow, Formalin-Fixed Paraffin-Embedded and Cytology Smear specimens. ON peripheral blood it provides: Detection of mutations, insertions and deletions for 147 clinically reported gene, detection and reporting of copy number variations (CNVs) for 136 genes and detection and reporting of lung cancer-related gene fusions in ALK, RET, and ROS1. This specific test is not NCCN supported. and contains many gene mutation tests.
Cancer care is becoming increasingly dependent on tumor markers to diagnose, anticipate prognosis, and select optimal therapy for patients. Various markers differ in the level of acceptability, how much knowledge stands behind each marker, validation: retro vs prospective and degree of literature acceptability and support. For cancers such as colon, lung and breast, guidelines had been issued. Even less is known about how to use markers to select between one or more diagnostic possibilities, as is being done in this case. As such, the testing is not medically necessary.
REFERENCES:
- Kadri S, Long BC, Mujacic I, Zhen CH, Wurst MN, Sharma S. Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. J Mol Diagn. 2017 Jan; 19(1): 43-56.
NCCN, CLL 2018